(Photo Courtesy: www.newhealthguide.org)
The value of the global Hepatitis B Virus (HBV) therapeutics market will increase modestly over the next 6 years, from almost $3 billion in 2014 to $3.5 billion by 2021, representing a Compound Annual Growth Rate (CAGR) of 2.3%, says business intelligence provider GBI Research.
The company's latest report states that this rise will occur across the eight major markets of the US, Canada, the UK, France, Germany, Italy, Spain and Japan, and will be primarily driven by increasing immigration from medium and high-prevalence countries.
Mr Priyatham Salimadugu, analyst for GBI Research, says: "The US, which has one of the largest shares of the HBV treatment market, sees considerable migration from high-prevalence countries, such as the Philippines, China, and Vietnam.
"While immigration will enlarge the patient pool, HBV treatment market expansion will be restricted by prophylactic vaccination in the US and much of Europe."
However, the analyst adds that the increasing use of the premium therapies tenofovir and entecavir will help to drive the market during the forecast period.